Type II endometrial carcinoma is an aggressive group of endometrial malignancies encompassing serous and clear cell carcinoma. It accounts for 10-15% of all endometrial cancers but carries a disproportionate share (40-50%) of endometrial cancer-related deaths. Typically occurs at an older age (mean 65-70) and can develop from atrophic endometrium independent of estrogen stimulation. Risk of deep myometrial invasion, peritoneal spread, lymph node metastasis, and distant metastasis is significantly higher than Type I. TP53 mutation is present in >90% of serous carcinomas. Imaging findings reflect aggressive biology: invasive mass arising even from thin endometrium, deep invasion, and extrauterine spread.
Age Range
60-80
Peak Age
68
Gender
Female predominant
Prevalence
Uncommon
Type II endometrial carcinoma develops through an estrogen-independent pathway — unlike Type I, it does not require endometrial hyperplasia as a precursor. The serous type is characterized by TP53 mutation (>90%) and extensive genomic instability — HER2/neu amplification is seen in up to 30%. The clear cell type shows ARID1A mutation, PI3K/AKT pathway activation, and hepatocyte nuclear factor (HNF) expression. Both subtypes have aggressive biology: early transperitoneal spread (ovarian carcinoma-like behavior), lymphovascular space invasion (LVSI), and deep myometrial invasion. Imaging findings reflect this pathology: serous carcinoma can arise even from atrophic (thin) endometrium — MRI shows focal mass or asymmetric thickening within thin endometrium. Peritoneal spread behaves like ovarian carcinoma — omental cake, ascites, and peritoneal implants may accompany. Marked diffusion restriction on DWI reflects high cellularity. Deep myometrial invasion is common — JZ may be completely disrupted. On contrast-enhanced MRI, the tumor shows an aggressive enhancement pattern.
Disproportionately large and invasive mass arising from atrophic/thin endometrium — the characteristic finding of Type II endometrial carcinoma. While Type I typically develops from thickened endometrium, Type II can arise from endometrium even below 4 mm.
T2-weighted MRI shows a mass arising from thin or atrophic endometrium — unlike Type I, it does not need to develop from thick endometrium. The mass shows intermediate-to-high T2 signal and may be heterogeneous. The JZ is usually completely disrupted because deep myometrial invasion is frequently (60-70%) present. The outer half of the myometrium may be invaded. Cervical stromal invasion and parametrial extension should be sought. Extrauterine spread (adnexal involvement, peritoneal implants) may be detected.
Report Sentence
A heterogeneous mass arising from thin endometrium is identified on T2-weighted sequences with complete junctional zone disruption and deep myometrial invasion, consistent with Type II endometrial carcinoma.
Type II endometrial carcinoma shows more pronounced diffusion restriction on DWI than Type I — ADC values are generally <0.8 x 10-3 mm2/s (vs. <0.9 in Type I). The mass shows very bright signal at high b-values (b=800-1000). Peritoneal implants may also show diffusion restriction — DWI is valuable for detecting extrauterine spread. ADC values inversely correlate with histological grade — the high-grade nature of Type II explains the low ADC values.
Report Sentence
Very pronounced diffusion restriction is identified in the endometrial mass on DWI with markedly low ADC values, consistent with high-grade endometrial carcinoma (Type II).
Contrast-enhanced CT shows ovarian carcinoma-like peritoneal spread in Type II endometrial carcinoma — omental thickening/cake, peritoneal nodular implants, ascites, and pelvic/para-aortic lymphadenopathy are seen. The primary uterine mass shows heterogeneous enhancement. Peritoneal implants are particularly seen in the cul-de-sac, paracolic gutters, and diaphragmatic undersurfaces. CT is ideal for staging in advanced disease — distant metastasis (lung, liver) is evaluated.
Report Sentence
A heterogeneous mass in the uterine cavity is identified on contrast-enhanced CT along with peritoneal implants, omental thickening, and ascites, consistent with advanced-stage endometrial carcinoma (Type II, peritoneal spread).
On dynamic contrast-enhanced MRI, Type II carcinoma shows an aggressive enhancement pattern — intense enhancement in early arterial phase and hypointense appearance relative to myometrium in delayed phase. Deep myometrial invasion is best evaluated in the delayed phase — the myometrium enhances intensely while the tumor remains relatively hypointense. Serosal invasion is recognized by continuity of tumor enhancement with the serosal surface. Parametrial invasion is detected by extension of enhancing tumor tissue into parametrial fat.
Report Sentence
The endometrial mass shows an aggressive enhancement pattern on dynamic contrast-enhanced MRI, appearing more hypointense than the myometrium in the delayed phase; deep myometrial invasion and [serosal/parametrial extension] are detected.
Transvaginal US may show Type II endometrial carcinoma as focal irregularity or asymmetric thickening in thin/atrophic endometrium — different from the diffuse thickening pattern in Type I. Even if endometrial thickness is within normal limits (<4 mm), focal heterogeneity or irregular endometrial-myometrial border is suspicious. Myometrial invasion may be detected as irregularity at the endometrial-myometrial border. Doppler shows increased vascular flow and low resistance index.
Report Sentence
Focal irregularity/heterogeneity is identified within thin endometrium on transvaginal US; Type II endometrial carcinoma cannot be excluded, endometrial biopsy and pelvic MRI are recommended.
FDG PET-CT shows higher FDG uptake in Type II endometrial carcinoma than Type I — SUVmax is generally between 10-25. PET-CT is particularly valuable for detecting extrauterine spread: pelvic and para-aortic lymph node metastases, peritoneal implants, and distant metastases (lung, liver, bone) are detected. It also plays an important role in treatment response evaluation and recurrence detection.
Report Sentence
High metabolic activity (SUVmax: [X]) is identified in the uterine mass on FDG PET-CT with [pelvic/para-aortic lymph node metastasis / peritoneal implants / distant metastasis] detected, consistent with advanced-stage Type II endometrial carcinoma.
On T1-weighted MRI, Type II endometrial carcinoma is generally isointense to myometrium, but focal T1 hyperintensity is seen in areas of intratumoral hemorrhage or necrosis. The clear cell subtype may show slightly different T1 signal characteristics due to glycogen-rich cytoplasm. In the presence of hematometra, T1-hyperintense fluid collection is seen in the uterine cavity. Pre-contrast T1 imaging provides baseline images for post-contrast comparison.
Report Sentence
Focal hyperintense areas consistent with intratumoral hemorrhage are identified within the endometrial mass on T1-weighted sequences.
Criteria
Most common Type II subtype (75-80%). TP53 mutation >90%, HER2/neu amplification up to 30%. Papillary architecture, high nuclear atypia, frequent mitoses. All serous carcinomas are considered FIGO grade 3.
Distinct Features
Ovarian carcinoma-like peritoneal spread, can arise from thin endometrium, deep invasion, TP53 mutation characteristic, variable chemotherapy response, poor prognosis (50-70% 5-year survival across all stages).
Criteria
20-25% of Type II. ARID1A mutation, PI3K/AKT activation. Glycogen-rich clear cytoplasm. Tubulocystic, papillary, or solid architecture. TP53 mutation less frequent than serous (30-40%).
Distinct Features
Glycogen-rich cytoplasm, usually diagnosed at advanced stage, chemotherapy resistance more common, stage-matched prognosis similar to serous, molecular similarity with renal clear cell carcinoma.
Criteria
Contains both epithelial and mesenchymal malignant components. Considered metaplastic carcinoma. Usually large, polypoid mass. Classified in Type II spectrum. Postmenopausal women, prior pelvic radiation history is a risk factor.
Distinct Features
Large polypoid mass, biphasic histology (carcinoma + sarcoma), heterogeneous MRI signal, aggressive course, worst prognosis among Type II subtypes.
Distinguishing Feature
Type I usually develops from thickened endometrium, shows more superficial invasion, younger patient group, slightly higher ADC values, peritoneal spread is rare.
Distinguishing Feature
Leiomyosarcoma arises from the myometrium (intramural) — not from the endometrial cavity; shows heterogeneous signal and necrosis areas on T2, coagulative necrosis appears T1 hyperintense, usually large (>5 cm) single mass.
Distinguishing Feature
Endometrial stromal sarcoma shows worm-like myometrial and vascular extension — does not fill the entire cavity like endometrial carcinoma, intravascular extension is pathognomonic, usually seen at a younger age.
Distinguishing Feature
Ovarian serous carcinoma shows primary ovarian mass — no accompanying uterine mass, bilateral adnexal mass is typical, CA-125 is generally higher, primary peritoneal spread starts from the ovarian surface.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralHistological diagnosis by endometrial biopsy is mandatory — serous or clear cell histology requires an aggressive treatment plan. Comprehensive staging surgery is the standard treatment: total hysterectomy + bilateral salpingo-oophorectomy + omentectomy + pelvic/para-aortic lymph node dissection + peritoneal biopsies + peritoneal cytology. In advanced disease, neoadjuvant chemotherapy (carboplatin + paclitaxel) may be applied. Trastuzumab may be added in HER2/neu-positive serous carcinomas. Adjuvant chemotherapy ± radiotherapy is recommended even at stage I (due to aggressive biology). Prognosis is significantly worse than Type I.
Type II endometrial carcinoma has aggressive biology. Over 60% are advanced stage at diagnosis. Surgical staging is mandatory (peritoneal cytology, omentectomy, lymphadenectomy). Adjuvant chemotherapy + radiotherapy is frequently required. 5-year survival is significantly lower than Type I (30-50%).